Breakthrough T1D

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bio

Advantagene Closes $14.2m Series A Round Immuno-oncology firm Advantagene Inc. raised $14.2m through the sale of its Series A convertible preferred shares to undisclosed investors. National Securi

Biopharma start-ups brought in half as much funding in the third quarter as in the second quarter, but the number of alliances for new and emerging therapeutics firms stayed the same. Big pharma made

Relay Therapeutics has launched with $57m in Series A venture capital to identify new drug targets and to find new ways of addressing difficult targets by studying proteins in motion rather than looki